GLP1R and retinal disorder: Compared with previous clinical trials with GLP-1 RAs, no additional safety signals (e.g. retinopathy) have emerged from the STEP clinical programme.42,50–54,59–61,66 Globally, patients treated with 2.4 mg semaglutide in the STEP clinical programme have discontinued the treatment due to adverse events at a higher rate (7%) than those on placebo (3.1%), primarily due to GI adverse events (4.5% versus 0.8%).42,51–54,59–61,66